Nachrichten zur SHIELD THERAPEUT. LS-,015 Aktie

Shares in Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) rose as much as 6% on Tuesday morning after the company announced a…

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) is gaining momentum. The company, known for its oral iron supplement ACCRUFeR, has reported a…

Shares of Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) rose in afternoon trading after the company announced a $10 million fundraising commitment…

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), a specialist in iron deficiency treatments, said its largest investor, AOP Health International, is backing...…

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)’s proposed $10 million equity agreement with AOP Health International Management “should provide some...…

Main Market miner Hamak Gold (LON: HAMA) has sold its 10.1% stake in Vela Technologies (LON: VELA). These are the…

Shares of Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) surged 27% in early trading after strong October sales of its iron deficiency…

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)) has reported strong sales of iron deficiency drug ACCRUFeR in October, bolstered by an increase…

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) reported strong sales for the third quarter of 2024. It unveiled plans to raise around…

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)s share price rose 8% following the announcement of successful phase III trial results for its…

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), a UK-based pharmaceutical company specialising in treatments for iron deficiency, announced on Wednesday...…

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) interim CEO Anders Lundstrom and CFO Santosh Shanbhag talked with Proactive about the companys impressive...…

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) progress was lauded by Peel Hunt in research that followed the speciality pharma groups interims on...…

…

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) hailed another strong period of growth as it delivered a more than three-fold increase in…

Shares in Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) rose 7% in early trading following the approval of its drug, Accrufer (ferric maltol), by Health...…

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) has announced that Health Canada has approved ACCRUFeR (ferric maltol) as a prescription drug for…

Shield Therapeutics (LON: STX) chief executive Greg Madison is stepping down and non-exec Anders Lundstrom will take over on an…

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) shares shot up 47% after it announced a stellar set of second-quarter trading numbers. The update,…

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) said that chief executive Greg Madison is stepping down from the role by mutual consent to pursue…

Shares in Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) were almost 7% higher in afternoon trading after the commercial-stage pharma group fortified…

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), the commercial-stage pharma company, has entered into a $5.7 million monetisation agreement with AOP Health...…

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), the commercial-stage pharma company, has entered into a $5.7 million monetisation agreement with AOP Health...…

Broker Peel Hunt has kept its rating on Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) under review following news that its Korean…

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)s partner, Korea Pharma, has filed a New Drug Application (NDA) for Accrufer with the countrys Ministry of...…

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)s full-year results, where the company reported a trebling of total revenues, were consistent with a…

Shield Therapeutics revenues almost trebled in 2023 as sales of its Accrufer/Feraccru iron deficiency treatment ramped up in the US.…

Shield Therapeutics revenues almost trebled in 2023 as sales of its Accrufer/Feraccru iron deficiency treatment ramped up in the US.…

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), the commercial-stage pharmaceutical company, confirmed it is still on course to be cash flow positive…